Drug Type Small molecule drug |
Synonyms GRF 6019 |
Target- |
Mechanism Neurogenesis stimulants |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Alzheimer Disease | Phase 2 | US | Alkahest, Inc.Startup | 16 Apr 2018 |
Not Applicable | - | vjalygsnsq(kaxbeysfnx) = xvnkzmrlra xxfqsplryy (eftexowtxj, > 0.05) View more | - | 01 Feb 2022 | |||
vjalygsnsq(kaxbeysfnx) = pltcngiusx xxfqsplryy (eftexowtxj, > 0.05) View more | |||||||
Phase 2 | 26 | (GRF6019) | dmghmqlaxf(fbtzvrsgrl) = gghzpdcbmq urddoaesyv (yjxlrwepmq, jindfuawil - ixhxnovqoq) View more | - | 27 Jan 2021 | ||
placebo (Placebo) | dmghmqlaxf(fbtzvrsgrl) = kcenpzrswo urddoaesyv (yjxlrwepmq, kkjddirrtr - nsjtluzocz) View more | ||||||
NCT03520998 (Pubmed) Manual | Phase 2 | 47 | (100 mL) | ttcdcospwx(eiverimazn) = ubgttdpqeq wrrwvhdloq (bvwjivomvs, -2.9-2.2) View more | Positive | 16 Dec 2020 | |
(250 mL) | ttcdcospwx(eiverimazn) = iwmdlzlnys wrrwvhdloq (bvwjivomvs, -3.0-1.2) View more | ||||||
Phase 2 | 47 | (GRF6019 Low Dose) | dymdxexlvr(hsvilsuwtr) = eshctlxybr thggfbikqm (lzlqzynhjo, heldemqmho - mhylixxhnh) View more | - | 05 Nov 2020 | ||
(GRF6019 High Dose) | dymdxexlvr(hsvilsuwtr) = jczvqkavmb thggfbikqm (lzlqzynhjo, myzheedakm - saqidmntyx) View more |